Learn
What is MOTS-c? The research and its FDA status
By the Everlon founding team · · How we write and review health content
Quick answer MOTS-c is a small peptide encoded in the DNA inside mitochondria, the parts of a cell that handle its energy metabolism, and FDA's reviewers found no published study of it given to people. In July 2026 an FDA advisory committee reviewed it, and news reports say the committee recommended adding it to the list of ingredients pharmacies may compound, even though FDA's own staff had proposed against it. MOTS-c is still not FDA-approved and, as of October 2026, not on FDA's 503A bulks list. What changed is enforcement: in a draft policy published for public comment on October 30, 2026, HHS says it does not intend to take enforcement action against MOTS-c compounded for subcutaneous or intramuscular injection when strict conditions are met; the draft is not final, and it is not approval.
What is MOTS-c?
Most of your genes sit in the cell's nucleus. Mitochondria, the structures that run much of a cell's energy metabolism, carry a small set of genes of their own. In 2015, researchers reported that a short stretch of that mitochondrial DNA encodes a peptide of 16 amino acids, which they named MOTS-c (Lee and colleagues, 2015). FDA's briefing document for the July 2026 meeting describes it the same way. The MOTS-c discussed online is a lab-made (synthetic) version.
MOTS-c has become popular online on the strength of early mouse research. Early-stage research tells scientists where to look next. It doesn't tell anyone what a product does in people.
What the research measured
The research is early, and almost all of it is in mice and cells.
- FDA's review staff found no published studies of MOTS-c given to people, by any route.
- The 2015 paper that named it, and a 2021 follow-up, tested it in mice and cells; the 2021 paper also measured the body's own MOTS-c in ten men, without giving anyone MOTS-c.
- FDA's staff noted that the studies didn't test a range of amounts, and that the molecular target through which it acts is unknown.
The detail, study by study:
The 2015 paper. Researchers at the University of Southern California and UCLA, with the National Institute on Aging, tested MOTS-c in cells and in mice. Male mice on a high-fat diet were given daily injections into the abdominal cavity for eight weeks, ten mice per group. Treated mice gained less weight than untreated mice on the same diet; in mice on a normal diet, body weight didn't differ. The paper also reported that MOTS-c switched on AMPK, an enzyme involved in energy metabolism, in cells. Some authors disclosed consulting roles with a biotechnology company, CohBar, Inc. (Lee and colleagues, 2015).
The 2021 paper. The same group, with collaborators in New Zealand and Canada, tested MOTS-c in mice aged 2, 12 and 22 months and reported differences in physical capacity on treadmill and other tests. In ten healthy young men who cycled on a stationary bike in New Zealand, it measured the body's own MOTS-c in tissue and blood, and found higher levels after exercise. Nobody in that part of the study was given MOTS-c. The paper also reported a trend toward longer life in mice treated late in life and said larger groups would be needed to confirm it; FDA's briefing describes that result more strongly than the paper does (Reynolds and colleagues, 2021).
What FDA summarized. The other published work is in rodents and cells and covers sugar and fat handling, bone and blood vessels. One test-tube study found MOTS-c broken down quickly in human blood, which raises the question of whether an injected product would reach active levels in people. Results in mice often don't carry over to people.
Full citations are in the Sources list below.
Where MOTS-c stands with FDA
MOTS-c is not an FDA-approved drug and, as of October 2026, is not on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with; FDA removed it from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA says is not a determination about the substance (how the categories work). In July 2026 FDA's reviewers proposed against adding it to the list, news reports (STAT, July 24, 2026) say the advisory committee voted to recommend adding it anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the vote and the rulemaking path).
MOTS-c under HHS's October 2026 draft policy
HHS, the department FDA belongs to, has drafted an enforcement-discretion policy for six peptides, MOTS-c among them. The National Community Pharmacists Association reported it on October 29, 2026. HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public." The draft says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with MOTS-c when all of the policy's conditions are met. For MOTS-c the routes it lists are subcutaneous or intramuscular injection. A route or form the policy doesn't list isn't covered.
The draft's seven conditions include a valid prescription for an individual patient, a tested ingredient from an FDA-registered manufacturer, MOTS-c as the only active ingredient, the label "This is a compounded drug product. Not for resale.", and serious adverse events reported to FDA's MedWatch program.
As drafted, the policy would last until a final rule decides whether MOTS-c goes on the bulks list, and HHS says it may revisit it "in whole or in part" if "a safety signal or product quality issue arises." It is not FDA approval, and it doesn't put MOTS-c on the bulks list. The full policy and all six peptides.
A prescription vs "research use only." The policy describes compounding for a named patient on a valid prescription, from a tested ingredient made by an FDA-registered manufacturer, labeled as compounded. A "research use only" product meets none of that: no prescriber reviews your history and no pharmacy prepares it for you. The two routes are compared here.
Before you trust anyone offering MOTS-c
Fair questions to put to any clinic or seller:
- Does it rely on HHS's draft policy, and how does it meet each condition? The draft policy covers injection only, and as of October 2026 MOTS-c is still not on the 503A bulks list.
- Which state-licensed pharmacy compounds it? You should be able to check its license with the state board of pharmacy.
- Who made the ingredient, and is there a certificate of analysis? Free base and acetate salt are different ingredients.
- Is a licensed provider in your state reviewing your health history, and can they say no?
- Is the claim based on people or mice?
- Where do reactions get reported? FDA takes reports through MedWatch.
Is this right for me?
Everlon doesn't offer this peptide. Whether any treatment suits you is a decision for a licensed provider who knows your health history, and the answer may be no.
Your real options right now:
- Hear from Everlon. The sign-up at the end of this page covers availability news, nothing else.
- See your own doctor about the goal behind your interest, whether that's weight, metabolism or exercise. They can go through approved options.
- Avoid "research use only" products. In August 2026, FDA wrote to online peptide sellers that the label didn't stop their products from being treated as drugs meant for people.
However the rules change, an independent licensed provider in your state would still review your history and decide.
How it works
- Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
- Hear from us only if Everlon offers it. We write about availability and nothing else, and you can unsubscribe anytime.
- A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers it, a provider licensed in your state reviews your health history first and can decline.
FAQ
Is MOTS-c FDA-approved? No. No FDA-approved product contains it.
Is MOTS-c legal to compound now? As of October 2026, it is still not on FDA's 503A bulks list. HHS's draft policy, open for public comment and not final, says HHS does not intend to take enforcement action against MOTS-c compounded for subcutaneous or intramuscular injection under its conditions. Questions about a particular seller are for a lawyer.
Did the FDA advisory committee approve MOTS-c? No. An advisory committee can only recommend, and FDA has to finish rulemaking first. Being on the bulks list would not make it an approved drug.
Has MOTS-c been tested in people? FDA's review found no published studies of MOTS-c given to people. A 2021 study measured the body's own MOTS-c after exercise in ten healthy young men.
Can a doctor prescribe MOTS-c? HHS's draft policy would cover MOTS-c compounded on a valid prescription for an individual patient, for subcutaneous or intramuscular injection, when every other condition is met. A prescription doesn't make it FDA-approved.
What this means for you
As of October 2026, MOTS-c still isn't on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against MOTS-c when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.
HHS's 2026 draft peptide compounding policy, explained covers all six peptides, and the July 2026 FDA peptide vote, explained covers what came before it.
Safety information
FDA's safety page (content current as of April 22, 2026) says, word for word: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans."
- Missing safety studies. FDA's briefing found no studies of single or repeated exposure, genetic damage, reproduction or cancer.
- Immune reactions. Injected peptides can clump together or carry manufacturing impurities, and FDA says it can't rule out immune reactions to them.
- Quality. FDA found MOTS-c poorly characterized for compounding and found no test data on impurities or clumping.
- Adverse-event reports. FDA's database held none through March 2025. Pharmacies compounding under 503A generally don't report to FDA, so a lack of reports doesn't mean a lack of problems.
- "Research use only" products. FDA's briefing says MOTS-c appears to be marketed on websites as an injectable, alone and mixed with other substances. FDA has said in writing that a "research use only" label doesn't change its view when a seller's website shows the product is meant for people. Products sold online as "research use only" are a different, unregulated market that Everlon does not participate in and that carries additional dangers. What the label means.
- Had a reaction? Tell a doctor and report it to FDA's MedWatch.
If this is a medical emergency, call 911.
Sources
- HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
- National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report). ncpa.org, accessed 2026-10-29
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID: 25738459. PubMed, accessed 2026-10-06
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID: 33473109. PubMed, accessed 2026-10-06
- FDA. FDA Briefing Document: MOTS-c-related bulk drug substances. Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov, accessed 2026-10-06
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories list), version updated April 22, 2026, archived copy; MOTS-c removed from Category 2 because its nomination was withdrawn. web.archive.org, accessed 2026-10-06
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov, accessed 2026-10-06
- FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act: Guidance for Industry. January 2025. fda.gov, accessed 2026-10-06
- FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
- STAT News. FDA advisory panel rejects compounding of one peptide, backs another. July 24, 2026 (news report of the committee votes). statnews.com, accessed 2026-10-06
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
- 21 U.S.C. 353a, Pharmacy compounding. Cornell Legal Information Institute. law.cornell.edu, accessed 2026-10-06
Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.
Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.